EODData

MEMBERSHIP REGISTER LOG IN

OTCBB, CPHRF: Cipher Pharmaceuticals Inc

05 Nov 2025
LAST:

10.54

CHANGE:
 0.06		OPEN:
10.39		HIGH:
10.64		ASK:
0.00		VOLUME:
6.4K
CHG(%):
0.60		PREV:
10.48		LOW:
10.29		BID:
0.00		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
05 Nov 2510.3910.6410.2910.546.4K
04 Nov 2510.4810.4810.2110.4811.7K
03 Nov 2510.4010.5210.4010.485.3K
31 Oct 2510.4210.5310.4110.515.1K
30 Oct 2510.2510.3810.1910.2510.9K
29 Oct 2510.4110.4310.2910.297.7K
28 Oct 2510.5510.5510.3810.55600
27 Oct 2510.4310.4810.3710.482.3K
24 Oct 2510.3610.3810.2710.356.9K
23 Oct 2510.2710.3910.2710.393.4K

COMPANY PROFILE

Name:Cipher Pharmaceuticals Inc
About:Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Natroba for the topical treatment of head lice and scabies infestations in adult and pediatric patients; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome. The company's licensed products comprise Absorica, an oral retinoid indicated for the treatment of f severe nodular and/or inflammatory acne, acne conglobate and recalcitrant acne; Lipofen, which is indicated as adjunctive therapy to diet to reduce elevated LDL-C, total-C, triglycerides, and Apo B, and to increase HDL-C, as well as to reduce triglycerides in adult patients; and Conzip, an opioid agonist indicated for the management of moderate to moderately severe chronic pain in adults. Its pipeline products include MOB-015, a topical formulation of terbinafine, which is in phase 3 clinical trial for treatment of onychomycosis; CF-101 (Piclidenoson) that is in phase 3 clinical trial for severe plaque psoriasis and rheumatoid arthritis; and DTR-001, a tattoo removal cream, which is in pre-clinical stage. The company was founded in 2000 and is headquartered in Mississauga, Canada.
Sector:Healthcare
Address:5750 Explorer Drive, Mississauga, ON, Canada, L4W 0A9
Website:https://www.cipherpharma.com
CUSIP:17253X105
CIK:0001358575
ISIN:CA17253X1050
FIGI:BBG00FY0BVK5

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:24.24 
Forward P/E:15.20 
Price to Sales:6.05 
Price to Book:2.65 
Revenue:47.59M 
EBITDA:16.56M 
Shares:25.39M 
Market Cap:267.73M 

TECHNICAL INDICATORS

MA5:10.450.9%
MA10:10.431.1%
MA20:10.440.9%
MA50:11.075.0%
MA100:10.371.6%
MA200:9.679.0%
STO9:76.10
STO14:77.79
RSI14:48.31
WPR14:-14.97 
MTM14:0.06
ROC14:0.01 
ATR:0.21 
Week High:10.640.9%
Week Low:10.193.5%
Month High:11.307.2%
Month Low:10.189.0%
Year High:12.5018.6%
Year Low:6.6359.0%